ReviewBMC neurology2012
Clinical correlates of grey matter pathology in multiple sclerosis.
Review in BMC neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Structure-function multilayer network integration and cognition in multiple sclerosis.Network neuroscience (Cambridge, Mass.) · 2026Article
- Social memory deficits and their neural correlates in multiple sclerosis.Scientific reports · 2025Article
- Brief international cognitive assessment for MS (BICAMS) and NEDA maintenance in MS patients: A 2-year follow-up longitudinal study.European journal of neurology · 2025Article
- Temporal trends of epilepsy in multiple sclerosis.Acta neurologica Scandinavica · 2022Article
- Seizures and multiple sclerosis‑more than an epidemiological association (Review).Experimental and therapeutic medicine · 2022Review
- Characteristics of cerebral blood flow in an Eastern sample of multiple sclerosis patients: A potential quantitative imaging marker associated with disease severity.Frontiers in immunology · 2022Article
- Widespread Disruptions of White Matter in Familial Multiple Sclerosis: DTI and NODDI Study.Frontiers in neurology · 2021Article
- Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.Patient preference and adherence · 2021Article
- Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis.International journal of molecular sciences · 2020Review
- Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003-2015.Frontiers in neurology · 2019Article
- Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.Brain : a journal of neurology · 2018Article
- How changes in brain activity and connectivity are associated with motor performance in people with MS.NeuroImage. Clinical · 2018Review
- Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes.BMC cancer · 2017Review
- Power estimation for non-standardized multisite studies.NeuroImage · 2016Article
- Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis.Human brain mapping · 2016Article
- Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.PloS one · 2016Observational
- Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.PloS one · 2016Article
- Early and Degressive Putamen Atrophy in Multiple Sclerosis.International journal of molecular sciences · 2015Article
- Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability.BMC neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, multiple sclerosis has been viewed as a disease predominantly affecting white matter. However, this view has lately been subject to numerous changes, as new evidence of anatomical and histological changes as well as of molecular targets within the grey matter has arisen. This advance was driven mainly by novel imaging techniques, however, these have not yet been implemented in routine clinical practice. The changes in the grey matter are related to physical and cognitive disability seen in individuals with multiple sclerosis. Furthermore, damage to several grey matter structures can be associated with impairment of specific functions. Therefore, we conclude that grey matter damage - global and regional - has the potential to become a marker of disease activity, complementary to the currently used magnetic resonance markers (global brain atrophy and T2 hyperintense lesions). Furthermore, it may improve the prediction of the future disease course and response to therapy in individual patients and may also become a reliable additional surrogate marker of treatment effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.